Orcas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 04-01-2025
- Paid Up Capital ₹ 3.69 M
as on 04-01-2025
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -30.74%
(FY 2021)
- Profit 80.77%
(FY 2021)
- Ebitda -35.00%
(FY 2021)
- Net Worth -0.07%
(FY 2021)
- Total Assets -5.24%
(FY 2021)
About Orcas Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.69 M, as per Ministry of Corporate Affairs (MCA) records.
Manivel Elaiyabharathi and Kannan Shanmugam serve as directors at the Company.
- CIN/LLPIN
U52311TZ2012PTC018721
- Company No.
018721
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Dharmapuri, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Orcas Pharmaceuticals Private Limited offer?
Orcas Pharmaceuticals Private Limited offers a wide range of products and services, including Insecticides and Pesticides, Non Selective Herbicide, Animal Medicines & Health Care, Veterinary Medicines, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, Antibacterial Drugs, Common Disease Medicines, Psoriasis Ointment.
Who are the key members and board of directors at Orcas Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manivel Elaiyabharathi  | Director | 27-Apr-2023 | Current |
| Kannan Shanmugam | Director | 06-Sep-2012 | Current |
Financial Performance of Orcas Pharmaceuticals.
Orcas Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 30.74% decrease. The company also saw a substantial improvement in profitability, with a 80.77% increase in profit. The company's net worth dipped by a decrease of 0.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orcas Pharmaceuticals?
In 2021, Orcas Pharmaceuticals had a promoter holding of 6.63% and a public holding of 93.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Orcas Pharmaceuticals?
Orcas Pharmaceuticals has a workforce of 9 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orcas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orcas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
